



Press Release

MEDIAN announces the award of new medical image interpretation and management projects for clinical trials for a total of €2.76M

- ✓ Award* of three Phase II projects sponsored by two major American biotech companies specializing in oncology

SOPHIA ANTIPOLIS, France – April 9, 2015 – MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, announced today that it has been selected to provide imaging solutions and services for three new clinical studies in oncology. Taken together, these three new projects total approximately €2.76M. These three studies are sponsored by two biotech companies specializing in oncology and immuno-oncology.

- A phase II study (non-small cell lung cancer - NSCLC) for a total of €1.08M
- A phase II study (colorectal cancer) for a total of €1.44M
- A phase II study (pancreatic adenocarcinoma) for a total of €248K.

Based on the West Coast of the United States, both of these companies are new clients for MEDIAN Technologies.

"The rise of biotech companies, primarily in the field of immuno-oncology, is a major driving force for MEDIAN Technologies' development in the clinical trial market," Jérôme Windsor, VP Business Development Pharma explains. "The highly innovative nature of our imaging offer is very attractive for biotech companies. This is why, since we signed our first contract with a biotech company in December 2013, we have been winning more and more projects with the players in this market segment."

As a reminder, on March 3, 2015 MEDIAN had announced project awards for a total of €1.53M. As of April 9, 2015, project awards and new signed contracts have reached €4.29M, compared to the €1.8M of orders received in the 1st quarter of 2014.

* A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.



ALMDT
LISTED
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world's largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to

biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. ISIN: FR0011049824– ticker: ALMDT The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechologies.com

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”



Contacts

MEDIAN Technologies Fredrik Brag, CEO +33 4 92 90 65 82 fredrik.brag@mediantechnologies.com	Press ALIZE RP Caroline Carmagnol Sophie Colin + 33 1 44 54 36 66 median@alizerp.com	Investors ACTIFIN Ghislaine Gasparetto ggasparetto@actifin.fr +33 1 56 88 11 11
--	---	---